BiotechTube
Home/Sagimet Biosciences/Eduardo Bruno Martins, MD, DPhil
EB

Eduardo Bruno Martins, MD, DPhil

Chief Medical Officer

Sagimet Biosciences

Therapeutic Areas

Metabolic DiseaseDermatologyOncology

Sagimet Biosciences Pipeline

DrugIndicationPhase
DenifanstatMetabolic Dysfunction-Associated Steatohepatitis (MASH) with moderate to advanced fibrosis (F2/F3)Phase 3 Ready
TVB-3567Acne VulgarisPhase 1
Denifanstat / Resmetirom CombinationMASHPhase 2

Leadership Team at Sagimet Biosciences

DH
David Happel
Chief Executive Officer & Director
TC
Thierry Chauche
Chief Financial Officer
MO
Marie O’Farrell, PhD
Chief Scientific Officer
GK
George Kemble, PhD
Chair of the Board
View full Sagimet Biosciences profile